Icon
+91 94997 68112
Login Register

Tikosyn - (0.125,0.25,0.5 mg; Capsule, Oral)

Dofetilide Pfizer
0.125,0.25,0.5 mg; Capsule, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
More Than 5
More Than 5
Indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Yes
***** (*****) *** *** ***** ** **** **** ** **** ****** '*** (*** *, ****) *** *** ************ *********. ******* *** ********** *** ******* **** ***** ********* ** *** ***** ** ***** ***** ******** *** ******* ** **** ****. ******(********) ** *********** ********** *** ****** ** ** ** ********** **** ********* *** *** ********** ****. ** ******* ******* ******* ***** * **** ** **** *** **** ****** *** *** *** *********. ******* ***** * *********** ********* *** ***-************ ***** *** ********** *** ********* *** *******(******* **** ******) ******** *** ******* ** ***** **** . ************ *** **** **** ** **** '*** ****** *** *** ********* ******* ********** *** ********* **** *** ** *** ********* *** **** ** ** **** *** **** *** ****** ****** *** ******* **** *** *, ****. ********* **** ***** **** ** ***** ********** *** ********* **** ********* ********* ** ***** ********* *** ****** *** ******* ******* **** ********. ***** ****** **** ******** *** ******* ** ** ********** ** **** **** *** **** *** ********* **** * **** ****** *** **** *** ******** *** **** ** **** ****. *** **** ********* *** * ***** *** *******.
  1. *** **, **** : ****** ****** * **** ******* ***** (***** ******) ** ***** ***** **** ** **** ******* '*** (*** *, ****).
  2. *** **, **** : ****** *** ***** ******* * ********** ********* ********* ** *** ***** ** ***** ***** (***** ******) ******** *** ******* ** **** ****.
  3. *** *, **** : ***** ******** *** ******* **** *** **** ***********.
  4. *** **, **** : ******* ***** * **** ** **** ****** '*** (*** *, ****) *** *** *** ********* ** ****** ****** ** ****.
  5. *** **, **** : ******* ***** * *********** ********* ******* ***-************ ** ****** '***.
  6. *** **, **** : ********** *** ********* **** ******* ***** *** ***** ** ********* *** *** ***** *** ******* ******** *** ******* *.* ***** ***** *********.
  7. *** **, **** : *** ******** ****** ********* **** ** ****** **** '*** (*** *, ****) ** ******.
  8. *** **, **** : ****** **** *** ** ** ** ********.
  9. *** **, **** : ********** ********* **** *** ** *** ********* *** **** ** ** **** ***.
  10. *** *, **** : ****** ***** * **** ******* ********* ** ********* ***** **** ** **** ****** '*** (*** *, ****) ** ******.
  11. *** **, **** : **** ****** (*******) ******** *** *******.
  12. *** **, **** : ***** ****** ******** *** ******* ******** ***** ** ** ****** ** *** **** ** ********** **** ***** ******.
  13. *** **, **** : ********** ********* **** ********* ** ****** ******* * ******** *** ** *** ** ********* *** ****** '*** '*** (*** *, ****) ** ******.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.